In the DMD context, recent studies have revealed that the delivery of CRISPR genome-editing tools by AAVs can reframe the mutated DMD gene and restore dystrophin expression in both DMD patient cells and in short-term mouse studies in vivo [93,94]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.